These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 15500557)

  • 1. Survival in HIV-infected patients is associated with hepatitis C virus infection and injecting drug use since the use of highly active antiretroviral therapy in the Lyon observational database.
    Voirin N; Trépo C; Miailhes P; Touraine JL; Chidiac C; Peyramond D; Livrozet JM; Ritter J; Chevallier P; Fabry J; Allard R; Vanhems P
    J Viral Hepat; 2004 Nov; 11(6):559-62. PubMed ID: 15500557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy.
    Rockstroh JK; Mocroft A; Soriano V; Tural C; Losso MH; Horban A; Kirk O; Phillips A; Ledergerber B; Lundgren J;
    J Infect Dis; 2005 Sep; 192(6):992-1002. PubMed ID: 16107951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of injecting drug use on mortality in Danish HIV-infected patients: a nation-wide population-based cohort study.
    Larsen MV; Omland LH; Gerstoft J; Larsen CS; Jensen J; Obel N; Kronborg G
    Addiction; 2010 Mar; 105(3):529-35. PubMed ID: 20402997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy.
    Tedaldi EM; Baker RK; Moorman AC; Alzola CF; Furhrer J; McCabe RE; Wood KC; Holmberg SD;
    Clin Infect Dis; 2003 Feb; 36(3):363-7. PubMed ID: 12539079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of diabetes in HIV infected veterans pre- and post-HAART and the role of HCV coinfection.
    Butt AA; Fultz SL; Kwoh CK; Kelley D; Skanderson M; Justice AC
    Hepatology; 2004 Jul; 40(1):115-9. PubMed ID: 15239093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort Study.
    Anderson KB; Guest JL; Rimland D
    Clin Infect Dis; 2004 Nov; 39(10):1507-13. PubMed ID: 15546088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risks of non-accidental mortality by baseline CD4+ T-cell strata in hepatitis-C-positive and -negative individuals initiating highly active antiretroviral therapy.
    Moore DM; Hogg RS; Braitstein P; Wood E; Yip B; Montaner JS
    Antivir Ther; 2006; 11(1):125-9. PubMed ID: 16518968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus coinfection and HIV load, CD4+ cell percentage, and clinical progression to AIDS or death among HIV-infected women: Women and Infants Transmission Study.
    Hershow RC; O'Driscoll PT; Handelsman E; Pitt J; Hillyer G; Serchuck L; Lu M; Chen KT; Yawetz S; Pacheco S; Davenny K; Adeniyi-Jones S; Thomas DL
    Clin Infect Dis; 2005 Mar; 40(6):859-67. PubMed ID: 15736020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiological, immunological and virological characteristics, and disease progression of HIV-1/HCV-co-infected patients from a southern Brazilian population.
    Reiche EM; Bonametti AM; Morimoto HK; Morimoto AA; Wiechemann SL; Matsuo T; Vissoci Reiche F; Vogler IH
    Int J Mol Med; 2008 Mar; 21(3):387-95. PubMed ID: 18288387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of hepatitis C in an ethnically diverse HIV-1-infected cohort in south London.
    Mohsen AH; Murad S; Easterbrook PJ
    HIV Med; 2005 May; 6(3):206-15. PubMed ID: 15876288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mortality due to liver failure and impact on survival of hepatitis virus infections in HIV-infected patients receiving potent antiretroviral therapy.
    Macías J; Melguizo I; Fernández-Rivera FJ; García-García A; Mira JA; Ramos AJ; Rivera JM; Pineda JA
    Eur J Clin Microbiol Infect Dis; 2002 Nov; 21(11):775-81. PubMed ID: 12461586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B and C virus coinfection in The TREAT Asia HIV Observational Database.
    Zhou J; Dore GJ; Zhang F; Lim PL; Chen YM;
    J Gastroenterol Hepatol; 2007 Sep; 22(9):1510-8. PubMed ID: 17645479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C.
    Macías J; Mira JA; López-Cortés LF; Santos I; Girón-González JA; González-Serrano M; Merino D; Hernández-Quero J; Rivero A; Merchante N; Trastoy M; Carrillo-Gómez R; Arizcorreta-Yarza A; Gómez-Mateos J; Pineda JA
    Antivir Ther; 2006; 11(7):839-46. PubMed ID: 17302246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy.
    Sullivan PS; Hanson DL; Teshale EH; Wotring LL; Brooks JT
    AIDS; 2006 May; 20(8):1171-9. PubMed ID: 16691069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival of HIV-infected injection drug users (IDUs) in the highly active antiretroviral therapy era, relative to sex- and age-specific survival of HIV-uninfected IDUs.
    Muga R; Langohr K; Tor J; Sanvisens A; Serra I; Rey-Joly C; Muñoz A
    Clin Infect Dis; 2007 Aug; 45(3):370-6. PubMed ID: 17599317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy.
    Grau I; Pallares R; Tubau F; Schulze MH; Llopis F; Podzamczer D; Liñares J; Gudiol F;
    Arch Intern Med; 2005 Jul; 165(13):1533-40. PubMed ID: 16009870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics and survival of HIV-infected patients not screened for hepatitis C virus infection in a hospital-based cohort.
    Bénet T; D'Oliveira A; Voirin N; Livrozet JM; Cotte L; Peyramond D; Chidiac C; Touraine JL; Fabry J; Trepo C; Allard R; Vanhems P
    J Viral Hepat; 2007 Oct; 14(10):730-5. PubMed ID: 17875008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to HAART and GB virus type C coinfection in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; Morsica G; Pizzaferri P; Ladisa N; Sighinolfi L; Chiodera A; Solmone M; Lalle E; Ippolito G; Monforte Ad; ;
    Antivir Ther; 2005; 10(1):109-17. PubMed ID: 15751768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of first antiretroviral treatment duration and outcome in HIV, HIV-HBV and HIV-HCV infection.
    Cooper CL; Mills E
    Int J STD AIDS; 2007 Aug; 18(8):546-50. PubMed ID: 17686217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.